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Review Article
Src family kinases: at the forefront of platelet activation
Yotis A. Senis, Alexandra Mazharian, and Jun Mori
Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental
Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom
Src family kinases (SFKs) play a central
role in mediating the rapid response of
platelets to vascular injury. They transmit
activation signals froma diverse repertoire
of platelet surface receptors, including
the integrin aIIbb3, the immunoreceptor
tyrosine–based activationmotif–containing
collagen receptor complex GPVI-FcR
g-chain, and the von Willebrand factor re-
ceptor complex GPIb-IX-V, which are essen-
tial for thrombus growth and stability.
Ligand-mediated clustering of these
receptors triggers an increase in SFK
activity and downstream tyrosine phos-
phorylation of enzymes, adaptors, and
cytoskeletal proteins that collectively
propagate thesignal andcoordinateplate-
let activation. A growing body of evidence
has established that SFKs also contribute
to Gq- and Gi-coupled receptor signaling
that synergizes with primary activation
signals tomaximallyactivateplatelets and
render them prothrombotic. Interestingly,
SFKs concomitantly activate inhibitory
pathways that limit platelet activation and
thrombus size. In this review, we discuss
past discoveries that laid the foundation
for this fundamental area of platelet signal
transduction, recent progress in our un-
derstanding of the distinct and overlap-
ping functions of SFKs in platelets, and
newavenues of research intomechanisms
of SFK regulation. We also highlight the
thrombotic and hemostatic consequences
of targeting platelet SFKs. (Blood. 2014;
124(13):2013-2024)
Src family kinases: critical initiators of platelet activation
Platelets are highly reactive fragments of megakaryocytes that
rapidly adhere to sites of vascular injury and nucleate formation of
thrombi that prevent excessive blood loss. They have also been
implicated in maintenance of vascular integrity, the inﬂammatory
response, and blood-lymphatic vessel separation. Platelets can also
have detrimental effects on health, forming life-threatening thrombi
on ruptured atherosclerotic plaques that culminate in myocardial
infarction and stroke. Conversely, reduced platelet counts and reac-
tivity can predispose to bleeding. Although highly effective in prevent-
ing thrombosis, current antiplatelet therapies have their limitations,
including increased risk of bleeding and resistance in some patients.
Moreover, antiplatelet drugs are contraindicated in conditions such
as hemorrhagic stroke, for which there are currently no effective
therapies. Thus, understanding themolecular basis of platelet activation
has important clinical implications.
The rapid response of platelets to vascular injury is mediated by
a diverse repertoire of tyrosine kinase–linked receptors, including
the von Willibrand factor (VWF) receptor complex GPIb-IX-V that
mediates tethering to sites of vascular injury1; the immunoreceptor
tyrosine–based activation motif (ITAM)–containing collagen re-
ceptor complex GPVI-FcR g-chain that mediates platelet activa-
tion2; the integrins a2b1 and aIIbb3 that mediate ﬁrm adhesion
and aggregation to exposed extracellular matrix3; the hemi-ITAM–
containing podoplanin receptor CLEC-24; and the ITAM-containing
low-afﬁnity immunoglobulin receptor FcgRIIA (Figure 1).5 Ligand-
mediated clustering of these receptors triggers transmission of
primary activation signals through the phosphorylation of down-
stream tyrosine residues in proteins. None of these receptors have
intrinsic kinase activity; instead, they rely on a family of protein-
tyrosine kinases (PTKs) called Src family kinases (SFKs) that are
either associated with or in close proximity to their cytoplasmic tails,
to transmit signals (Figure 1). Downstream effectors of SFKs include
adaptors, enzymes, and cytoskeletal proteins that collectively coor-
dinate cytoskeletal remodeling, degranulation, membrane ﬂipping,
and integrin activation. A growing body of evidence has estab-
lished that SFKs also contribute to signaling via G protein–coupled
receptors (GPCRs), including the Gq-coupled thrombin protease-
activated receptors 1 and 4 (PAR-1 and PAR-4)6-9 and the
Gi-coupled adenosine 59-diphosphate (ADP) receptor P2Y12
10-12 that
synergize with primary activation signals to maximally activate
platelets. Some SFKs concomitantly initiate inhibitory pathways
involving immunoreceptor tyrosine–based inhibition motif (ITIM)–
containing receptors, lipid and protein-tyrosine phosphatases (PTPs)
that attenuate platelet activation,13 thus limiting thrombus size.
SFKs have been intensively investigated in platelets for more
than 2 decades, yet much remains to be learned about their functions
and regulation. The primary aim of this review is to discuss our
current understanding of the functional roles of SFKs in platelets
by highlighting key discoveries that laid the foundation for this ﬁeld
and by introducing new concepts and future areas of research. We
also discuss the thrombotic and hemostatic consequences of inhibiting
platelet SFKs, which has broad clinical implications because PTK
inhibitors are increasingly used in the treatment of cancer and
inﬂammatory and autoimmune diseases.
Structure, function, and expression of SFKs
Cellular-Src (short for “sarcoma”) was the ﬁrst proto-oncogene
discovered and its protein product Src is the prototype of this family
of PTKs. There are 8members of the family, including Src, Yes, Fyn,
and Fgr, whichmake up the SrcA subfamily, and Lyn, Hck, Lck, and
Blk, which make up the SrcB subfamily (Table 1).14 The Src-related
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kinases Frk, Brk, and Srm are referred to as SFKs, but they lack
structural features common to all SFKs. Src, Yes, and Fyn are widely
expressed, whereas the remaining SFKs are primarily expressed in
hematopoietic cells.
SFKs are involved in a broad range of cellular processes, including
proliferation, differentiation, survival, adhesion, and motility. For
a time, platelets were the primary cell of choice for studying SFK
function because they express high levels of SFKs and are easy to
obtain.15 Seven SFKs (Src, Yes, Lyn, Hck, Fyn, Fgr, and Lck) have
been reported in human platelets and four (Src, Lyn, Fyn, and Fgr)
have been reported in mouse platelets (Table 1).16-21 A number of
structurally distinct broad-spectrum SFK inhibitors (PP1, PP2,
SU6656, PD0173952) and knockout mouse models have been
used to elucidate the contributions of these SFKs to platelet signal
transduction and function. The most well-established functions are
summarized in Table 1.
SFKs consist of an N-terminal myristoyl group attached to an Src
homology 4 (SH4) domain, followed by a unique region, an SH3
domain, an SH2 domain, a proline-rich SH2-kinase linker region,
and an SH1 or kinase domain (Figure 2).14 Myristoylation of the
N-terminus facilitates binding to the inner leaﬂet of the plasma
membrane, which is required for function. Yes, Fyn, Fgr, Lyn, Hck,
and Lck also contain a cysteine residue within their myristoylation
peptide that supports palmitoylation and localization to specialized
regions of the plasmamembrane referred to as lipid rafts that contain
high concentrations of glycosphingolipids and cholesterol and
serve as organizing centers of signaling proteins and receptors. Src
and Blk are not palmitoylated, and hence they are excluded from
lipid rafts. The SH3 and SH2 domains of SFKs mediate intra- and
intermolecular interactions with proline-rich regions and phospho-
tyrosine residues, respectively. In addition, all SFKs contain 2 highly
conserved tyrosine residues, one in their C-terminal tail and the other
in their activation loop that are critical for regulating SFK activity
(Figure 2).22 Phosphorylation of the C-terminal tyrosine residue by
C-terminal Src kinase (Csk) or its family member Csk homologous
kinase inhibits SFK activity,23 whereas trans-autophosphorylation
of the activation loop tyrosine residue maximally activates the
SFK (Figure 2).22 Conversely, dephosphorylation of the C-terminal
inhibitory and activation loop tyrosine residues by PTPs increases and
decreases SFK activity, respectively (Figure 2).24
For the remainder of this review, we focus speciﬁcally on the 3
most highly expressed and studied SFKs in platelets, namely Src,
Lyn, and Fyn, all of which have been implicated in integrin, ITAM-
containing, and GPIb-IX-V receptor signaling. Src and Fyn are
primarily regarded as positive regulators, whereas Lyn plays a dual
role as a positive and a negative regulator of platelet activation. All
3 SFKs also contribute to Gq- and Gi-coupled receptor signaling. Fgr
andYes are expressed at much lower levels than Src, Lyn, and Fyn in
platelets and have been implicated in ITAM-containing and integrin
receptor signaling, respectively.21,25 Below, we discuss our current
understanding of how Src, Lyn, and Fyn work in conjunction to
regulate an optimal level of platelet activation.
Src: positive regulator of aIIbb3 signaling
aIIbb3 is the most abundant platelet surface receptor and is essen-
tial for adhesion, aggregation, and clot retraction. Inside-out signals
emanating from various activation receptors trigger aIIbb3 to
adopt a high-afﬁnity conformation (Figure 3A). Subsequent ligand-
mediated clustering initiates outside-in signaling that facilities platelet
activation, spreading, secretion, and clot retraction. Src is the most
abundant SFK in human platelets26 and is essential for initiating
and propagating signals from aIIbb3.27
A proportion of Src associates with the cytoskeleton upon platelet
activation allowing it to phosphorylate key substrates, including
cortactin and WASp, that regulate cytoskeletal remodeling.28,29 A
pool of Src is also constitutively associated with the b3 subunit of
aIIbb3.25 This interaction, mediated by the SH3 domain of Src and
the RGT amino acid sequence in the extreme C-terminal tail of b3,
disrupts the intramolecular SH3-proline-rich linker interaction and
primes Src.25 b3-associated Src is maintained in an inactive con-
formation by Csk, which forms a complex with b3 and Src in resting
platelets and phosphorylates the C-terminal inhibitory tyrosine
of Src (human Tyr529; mouse Tyr534) (Figure 3A).25,30,31 Csk
gets replaced by the nontransmembrane PTP-1B, released from the
cytosolic surface of the endoplasmic reticulum upon ﬁbrinogen
binding,which dephosphorylates Tyr529 and activates Src.30,32 The
receptor-like PTP CD148 contributes toaIIbb3 outside-in signaling
by maintaining a pool of active SFKs at the plasma membrane and
also by dephosphorylating the C-terminal inhibitory tyrosine residue
of all SFKs (Figure 3A).33 Subsequent ligand-mediated clustering
of the integrin induces trans-autophosphorylation of human
Tyr418 (mouse Tyr423) in the activation loop and maximal acti-
vation of Src.30,33 Downstream Src-dependent phosphorylation
events include Tyr773 and Tyr785 in human b3 (mouse Tyr747
and Tyr759) that provide docking sites for myosin light chain and
the adaptor Shc,34 adaptor and cytoskeletal proteins (paxillin,
vinculin, and actinin) that provide docking sites for assembly of
signaling complexes,35-37 tyrosine kinases (FAK, Pyk, and Syk),38
small guanosine triphosphatase (Rap1B), guanine nucleotide
exchange factors (Vav1 and Vav3),39,40 and the lipid kinase
phosphoinositide 3 kinase (PI3K) that propagate the signal.38,41
Src-dependent activation of phospholipase Cg2 (PLCg2) results
in the hydrolysis of phosphatidylinositol 4,5-bisphosphate
(PI4,5P2) to the second messengers diacylglycerol (DAG) and
inositol triphosphate (IP3) that activate the serine/threonine
protein kinase C (PKC) family and facilitate Ca21 mobilization,
respectively.42 Tyrosine phosphorylation of the ITAM-containing
FcgRIIA receptor by SFKs provides a high-afﬁnity docking site
Figure 1. Src family kinases initiate primary activation in platelets. Src family
kinases (SFKs) phosphorylate adaptors, enzymes, and cytoskeletal proteins down-
stream of a variety of platelet surface receptors that collectively coordinate
platelet activation. Dark green box, ITAM; light green box, hemi-ITAM. LEC,
lymphatic endothelial cell.
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for the tandem SH2 domain-containing tyrosine kinase Syk, which
facilitates spreading on ﬁbrinogen (Figure 3A).43
Src and Lyn concomitantly activate the SH2 domain–containing
inositol 5-phosphatase 1 (SHIP-1) that attenuatesaIIbb3 signaling.
SHIP-1 associates with Src, Lyn, and b3 and is phosphorylated by
Src and Lyn (Figure 3B).44,45 Activated SHIP-1 subsequently dephos-
phorylates phosphatidylinositol 3,4,5-trisphosphate (PI3,4,5P3) to
PI3,4P2, which downregulates membrane localization of pleckstrin
homology domain–containing PLCg2, IP3, and DAG generation and
Ca21 mobilization.44,45 Enhanced spreading of Lyn-deﬁcient mouse
platelets onﬁbrinogen is thus explainedby loss of SHIP-1 activation.45
The ITIM-containing inhibitory receptors PECAM-1 and G6b-B
also get phosphorylated downstream of aIIbb3, but their exact con-
tributions to aIIbb3 signaling remain ambiguous. Both associate
with Shp1 and Shp2 following SFK-dependent phosphorylation of
tyrosine residues within tandem ITIM/immunoreceptor tyrosine-
based switch motifs.46,47 Paradoxically, mouse platelets lacking
PECAM-1 exhibit reduced spreading onﬁbrinogen and clot retraction,
and G6b-B–deﬁcient platelets exhibit reduced lamellipodia formation
on ﬁbrinogen in the presence of thrombin (Figure 3B),46 suggesting
that both receptors facilitate aIIbb3-mediated responses.47
Mouse platelets lacking Src exhibit severely impaired tyrosine
phosphorylation and spreading on ﬁbrinogen.21,31 Similarly, disrup-
tion of the Src-b3 interaction, either by deleting or mutating the b3
RGT sequence reduces outside-in signaling and platelet spreading on
ﬁbrinogen and clot retraction, which culminates in reduced thrombus
formation and a mild bleeding diathesis.48 However, defects are
not as severe as those seen in the presence of SFK inhibitors,31,49
suggesting that there is functional redundancy between SFKs.
Indeed, deletion of Lyn or Fyn in combination with Src exacerbates
integrin-mediated functional defects.21
Dual roles of Lyn in ITAM-containing and
integrin receptor signaling
Lyn is highly expressed in human platelets19 and is the most
abundant SFK in mouse platelets.21 Unlike Src, it is localized to
lipid and nonlipid rafts and performs dual functions as positive and
negative regulator of ITAM-containing receptor and integrin sig-
naling. A pool of active Lyn is constitutively associated with the
cytoplasmic tail of GPVI, allowing for rapid signal transduction
(Figure 4A).50-53 This interaction, mediated by the SH3 domain of
Lyn and the proline-rich juxtamembrane region of GPVI, activates
and maintains Lyn in close proximity to the FcR g-chain. Lyn-
mediated phosphorylation of the tandem tyrosine residues in the
FcR g-chain ITAM provides a high-afﬁnity docking site for Syk
(Figure 4A). Lyn subsequently phosphorylates and activates Syk,
and together they propagate the signal. The phosphorylation
status of GPVI-associated Lyn suggests that it is maximally
active, because it is phosphorylated on its activation loop tyrosine
(human and mouse Tyr396) and not on its C-terminal inhibitory
tyrosine residue (human and mouse Tyr507).53 It is hypothesized
that this allows GPVI to signal more rapidly than a typical
ITAM-containing immune receptor lacking associated SFKs.
How the FcR g-chain remains only marginally phosphorylated
under resting conditions is not known.54 One hypothesis is that
the FcR g-chain is embedded in the plasma membrane and is
inaccessible to Lyn.55 Another is that the FcR g-chain gets dephos-
phorylated at a faster rate than it gets phosphorylated. Perhaps
another inhibitory mechanism is at play. This is an intriguing
question that warrants investigation.
Mice lacking Lyn exhibit a complex platelet phenotype,
including mild thrombocytopenia after 10 weeks of age, sec-
ondary to enhanced inﬂammation, increased numbers of mega-
karyocyte progenitors and mature megakaryocytes in the bone
marrow, and aberrant platelet function.56,57 The phenotype can be
partially explained by increased Mpl-mediated Erk1, Erk2, and
Akt activation in Lyn-deﬁcient megakaryocytes. SHIP-1 phos-
phorylation is concomitantly decreased, suggesting that Lyn
negatively regulates the Ras/MAPK and PI3K/Akt pathways in a
SHIP-1–dependent manner.57 More recently, Lyn was implicated
as a membrane cholesterol sensor in megakaryocyte progenitors,
linking platelet production with membrane cholesterol levels and
atherogenesis.58 Increased membrane cholesterol accumulation
in mouse megakaryocyte progenitors led to increasedMpl expression
and signaling, platelet overproduction, arterial thrombosis, and
atherogenesis in a hypercholesterolemicmouse model.58 Mechanis-
tically, Lyn was proposed to be the dominant SFK mediating
downregulation ofMpl via the E3-ubiquitin ligaseCbl.58 Excessive
membrane cholesterol accumulation led to decreased Lyn kinase
activity and reduced Cbl-mediated downregulation of Mpl by
Tpo.58,59
Platelets from Lyn-deﬁcient mice exhibit a delay in the onset of
GPVI-induced tyrosine phosphorylation and functional responses,
followed by a recovery of tyrosine phosphorylation and enhanced
responses at later time points.51 These ﬁndings suggest that Lyn
activates negative feedback pathways concomitantly with initiating
GPVI signaling. The delay inGPVI signaling in the absence of Lyn is
likely the result of less efﬁcient phosphorylation of the FcR g-chain
by other SFKs, whereas the enhanced responses at later stages may
be the result of the absence of Lyn-dependent negative feedback
signals, most likely mediated by PECAM-1, G6b-B, and SHIP-1
(Figure 4B). Lyn associates with the cytoplasmic tail of PECAM-1,
facilitating phosphorylation of the tandem ITIM/immunoreceptor
tyrosine-based switch motifs and binding of Shp2.60 Deletion of
PECAM-1 and Lyn does not have an additive effect, which sup-
ports the notion that they act via the same inhibitory pathway.13
Whether Lyn also contributes to tyrosine phosphorylation of
G6b-B remains to be determined.47 Lyn also associates with and
Figure 2. General structure of SFKs. All SFKs share a common structure consisting
of an N-terminal myristoyl group attached to an SH4 domain, a unique region, an SH3
domain, an SH2 domain, an SH2-kinase proline-rich linker region, and an SH1 or
kinase domain. Yes, Fyn, Fgr, Lyn, Hck, and Lck contain a cysteine residue within the
myristoylation peptide sequence that gets palmitoylated and mediates localization
to lipid rafts. There is a conserved tyrosine residue in the activation loop and one
in the C-terminal tail. Phosphorylation of the activation loop tyrosine by trans-
autophosphorylation increases SFK activity, whereas phosphorylation of the C-terminal
tyrosine by C-terminal Src kinase (Csk) or the structurally related Csk homologous
kinase (Chk) inhibits SFK activity. Dephosphorylation of the activation loop and
C-terminal inhibitory tyrosine residues by PTPs attenuates and increases SFK activity,
respectively. Green denotes activation, and red denotes inhibition of SFK activity.
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phosphorylates SHIP-1 and PKCd downstream of GPVI, thus
negatively regulating cytosolicCa21 concentration and dense granule
secretion (Figure 4B).45,61
Mouse platelets lacking Src, Fyn, or Fgr along with Lyn respond
less well to GPVI-speciﬁc agonist collagen-related peptide (CRP) and
ﬁbrinogen compared with platelets lacking any of these SFKs on
their own, suggesting a degree of functional redundancy.21 The one
unique aspect of the Lyn knockout phenotype is the hyperreactivity
to CRP and ﬁbrinogen, which suggests that only Lynmediates these
inhibitory functions in mouse and presumably human platelets.21
Figure 3. SFKs in integrin aIIbb3 proximal signaling. (A) The integrin aIIbb3 is in a low-affinity conformation on the surface of resting platelets. The SFKs Src and Fyn
constitutively associate with the cytoplasmic tail of the b3 subunit via their SH3 domains. Src is maintained in an inactive conformation by Csk, which forms a complex with b3
and Src. Inside-out signaling induces the integrin to adopt a high-affinity conformation and fibrinogen binding. Csk subsequently dissociates from the complex and is replaced
by the nontransmembrane PTP-1B that dephosphorylates the C-terminal inhibitory tyrosine residue of Src and activates it. The receptor-like PTP CD148 plays a major role in
maintaining a pool of activated SFKs at the plasma membrane that contribute to aIIbb3 signaling. Fibrinogen-mediated clustering of the integrin induces trans-
autophosphorylation of the activation loop tyrosine residue of SFKs and maximal activation. (B) The ITIM/immunoreceptor tyrosine-based switch motif (ITSM)–containing
inhibitory receptors PECAM-1 and G6b-B are phosphorylated by SFKs downstream of aIIbb3. The SH2 domain–containing nontransmembrane PTPs Shp1 and Shp2 bind to
the tandem phosphorylated ITIM/ITSM. The exact contributions of PECAM-1 and G6b-B to aIIbb3 signaling remain ambiguous and are denoted by the dashed arrow. SFKs
also phosphorylate and activate SH2 domain-containing SHIP-1, which forms a complex with SFKs and the b3 tail. SHIP-1 attenuates integrin signaling by dephosphorylating
PI3,4,5P3 to PI3,4P2 and disrupting membrane localization of (PLCg2), which binds to PI3,4,5P3 via its pleckstrin homology (PH) domain. PLCg2 must associate with the
plasma membrane in order to hydrolyze PI4,5P2 to the second messenger’s DAG and IP3 that activate serine/threonine PKC and facilitate Ca
21 mobilization, respectively.
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Fyn: positive regulator of ITAM-containing
and integrin receptor signaling
Fyn is highly expressed in human andmouse platelets.18,21 Like Lyn,
Fyn is palmitoylated and constitutively associated with the proline-
rich region in the cytoplasmic tail of GPVI via its SH3 domain.50,51
In vitro interaction studies demonstrate that the Lyn SH3 domain
preferentially binds to this site.53 Despite these similarities, Fyn- and
Lyn-deﬁcient platelets exhibit unique GPVI-mediated defects.51 Ag-
gregation and secretion of Fyn-deﬁcient platelets are reduced in
response to low and intermediate concentrations ofCRP.21,51 Tyrosine
phosphorylation of the FcR g-chain, Syk, and the downstream
adaptors LAT and SLP-76 are also reduced in Fyn-deﬁcient platelets
in response to a low concentration of CRP.51 However, Fyn-deﬁcient
platelets aggregate normally in response to high concentrations
of thrombin, collagen, and ADP, which suggests that other SFKs
compensate in the absence of Fyn.51 Indeed, additive effects are
seen if Lyn or Src are deleted in addition to Fyn.21 The Src/Fyn
double-knockout result is particularly intriguing, because Src is not
detectable in lipid rafts.21
A proportion of Fyn is also constitutively associated with the
cytoplasmic tail of the b3 subunit of aIIbb3. Unlike Src, which
binds to the extreme C-terminus of b3, Fyn associates with amino
acid residues 721 to 725 (IHDRK) in the juxtamembrane region
and remains associated with b3 following thrombin-induced
Figure 4. SFKs in GPVI-FcR g-chain proximal
signaling. (A) The SFKs Lyn and Fyn constitutively
associate with the proline-rich juxtamembrane region of
GPVI via their SH3 domains. This interaction unclamps
and activates the SFKs. The receptor-like PTP CD148
maintains the SFKs in an activated state by dephosphor-
ylating their C-terminal inhibitory tyrosine residues.
Collagen-mediated clustering of the receptor induces
trans-autophosphorylation of the activation loop tyro-
sine residue and maximal SFK activation. SFKs
phosphorylate tandem tyrosine residues in the ITAM-
containing FcR g-chain, which provides a high-affinity
docking site for the tandem SH2 domain–containing
protein-tyrosine kinase Syk. SFKs also phosphorylate
and active Syk. SFKs and Syk phosphorylate down-
stream effectors and propagate the signal. (B) The
ITIM/ITSM-containing inhibitory receptors PECAM-1
andG6b-B inhibit GPVI-FcR g-chain signaling. Lyn phos-
phorylates tandem tyrosine residues in the ITIM/ITSM
in the cytoplasmic tails of PECAM-1 and G6b-B that
provides a high-affinity binding site for the SH2
domain–containing nontransmembrane PTPs Shp1
and Shp2. Lyn associated with the cytoplasmic tail of
PECAM-1 facilitates phosphorylation. Lyn also phos-
phorylates and activates SH2 domain–containing SHIP-1
and PKCd that form a complex and inhibit dense granule
secretion.
2018 SENIS et al BLOOD, 25 SEPTEMBER 2014 x VOLUME 124, NUMBER 13
platelet aggregation.62 Loss of the Src binding site is thought to
be calpain-mediated.63 Fyn-deﬁcient mouse platelets exhibit a
less severe spreading defect on ﬁbrinogen compared with Src-
deﬁcient platelets, demonstrating the dominant role of Src
downstream of aIIbb3.21,62 Mouse platelets lacking Src and Fyn
exhibit a comparable spreading defect to that of Src-deﬁcient
platelets.21
Distinct roles of SFKs in ITAM- and
hemi-ITAM–containing receptor signaling
SFKs play a central role in initiating signaling via the ITAM-
containing receptors GPVI-FcR g-chain and FcgRIIA53,64; however,
their role downstream of the hemi-ITAM–containing podoplanin
receptor CLEC-2 is incompletely deﬁned. CLEC-2 has garnered
much attention recently for its involvement in blood-lymphatic
vessel separation.65 Unlike the FcR g-chain and FcgRIIA that
contain tandem tyrosine residues in their ITAMs, CLEC-2 contains
a single tyrosine residue in its hemi-ITAM that binds a single Syk
SH2 domain with low afﬁnity when phosphorylated.66 Tandem
phosphorylated CLEC-2 receptors are thus required to provide a
high-afﬁnity docking site for a single Syk molecule.66 Rhodocytin-
mediated tyrosine phosphorylation of CLEC-2 and downstream
signaling proteins is inhibited in human platelets treated with PP2,
which suggests an important role of SFKs in initiating CLEC-2
signaling.67 However, phosphorylation of the CLEC-2 is normal in
rhodocytin-stimulated Src-, Lyn- and Fyn-deﬁcient mouse plate-
lets.68 Surprisingly, rhodocytin-mediated CLEC-2 phosphorylation
is normal, and downstream phosphorylation of PLCg2 and platelet
activation are abolished in mouse platelets treated with an SFK
inhibitor.68 On the basis of these ﬁndings, SFKs are thought to play
an auxiliary role in initiating CLEC-2 signaling, activating Syk, and
amplifying proximal signaling events, whereas Syk plays the main
role in phosphorylating CLEC-2.66
SFKs initiate GPIb-IX-V signaling
VWF engagement of GPIb-IX-V induces inside-out signaling to
aIIbb3, which mediates ﬁrm adhesion to sites of vascular injury and
thrombus formation.1 Src, Lyn, and Fyn have all been implicated in
the early stages of GPIb-IX-V signaling. Lipid raft localization and
ﬁlamin-dependent cytoskeletal association are also required for
optimal GPIb-IX-V signaling.69,70 Src and Lyn associate with the
cytoplasmic tail of GPIba and the cytoskeleton following VWF
engagement (Figure 5).71 PI3K, FAK, SHIP-1, and PTP-1B sub-
sequently associate with the plasmamembrane in an SFK-dependent
manner.72 Concomitantly, Fyn interacts with PKCd, inducing trans-
phosphorylation and reciprocal activation.73 Studies using Lyn-
deﬁcient mouse platelets revealed that Lyn is essential for initiating
GPIb-IX-V signaling, whereas Src enhances it.74 The FcR g-chain
is also phosphorylated downstream of GPIb-IX-V and associates
with theGPIba subunit (Figure 5).75 Syk binds to the phosphorylated
FcR g-chain and transmits signals in a manner similar to that of an
ITAM-containing receptor; however, GPVI-FcR g-chain transmits
a stronger activation signal relative to GPIb-IX-V. Downstream
targets of SFKs include the adaptor proteins LAT and ADAP,
PLCg2, the tyrosine kinase Btk, and the mitogen-activated protein
kinases Erk1 and Erk2.1 FcgRIIA is also reported to be phos-
phorylated downstream of GPIb-IX-V and is required for signaling
(Figure 5).76 However, subsequent studies demonstrated that GPIb-
IX-V signals in an ITAM-independent manner, culminating in
PLCg2 activation and Ca21 oscillations.77,78 Inhibition of PI3K and
Ca21 chelation blockedGPIb-IX-V–mediated integrin activation but
not tyrosine phosphorylation, whereas inhibition of SFKs blocked
Figure 5. SFKs in GPIb-IX-V proximal signaling. The
SFKs Src and Lyn associate with the GPIba subunit
and initiate inside-out signaling. Binding of VWF to the
extracellular region of GPIba induces SFK activation
and phosphorylation of downstream substrates, in-
cluding the ITAM-containing FcR g-chain (FcR g) and
FcgRIIA, both of which act as high-affinity docking sites
for the tandem SH2 domain–containing protein-tyrosine
kinase Syk. The FcR g-chain is reported to associate
with the GPIba subunit. However, GPIb-IX-V can signal
in an ITAM-independent manner. Fyn and PKCd asso-
ciate and reciprocally activate one another, propagating
the signal.
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all GPIb-IX-V–mediated responses,78 highlighting the central role
played by SFKs in this signaling pathway.
SFKs in GPCR signaling
GPCRs signal via heterotrimeric guanine nucleotide-binding proteins
(Gabg proteins). However, a growing body of evidence has estab-
lished that SFKs associate with GPCRs and contribute to down-
stream signaling.79 Platelets express a variety of activating GPCRs
that are broadly divided intoGq- andGi-coupled receptors.Gq-coupled
receptors for thrombin (PAR-1 and PAR-4), ADP (P2Y1), thrombox-
ane A2 (TxA2, TP), and serotonin (5-HT2A) signal by activating
PLCb and inducing Ca21 mobilization (Figure 6Ai). In contrast,
Gi-coupled receptors for ADP (P2Y12) and adrenalin (a2A) signal by
inhibiting adenylate cyclase and activating PI3K (Figure 6B).80
Signals transmitted by these receptors synergize with primary
activation signals from tyrosine kinase–linked receptors to maximally
activate platelets.
Unlike integrin and ITAM-containing receptors, SFKs play an
auxiliary role in Gq-coupled receptor signaling, lying downstream
of PLCb and Ca21mobilization (Figure 6Ai).7 General SFK inhibi-
tors do not completely inhibit platelet activation, but rather they
block or attenuate speciﬁc aspects of platelet function, such as
TxA2 production, platelet aggregation, and adenosine triphosphate
secretion.7 PAR-4–mediated SFK activation is inhibited by Ca21
chelation, which supports the notion that SFKs are activated down-
stream of Ca21 mobilization.7 SFKs have been reported to lie
upstream of PI3K9 and work in conjunction with PKC to propagate
PAR-4 signaling.81 PAR-4–mediated platelet activation is only
partially inhibited in the presence of a PKC inhibitor, Ca21 chelator,
Figure 6. Src family kinases in Gq- and Gi-coupled
receptor signaling. (Ai) The Gq-coupled PAR-4 signals
via the activation of phospholipase b (PLCb), which
hydrolyses PI4,5P2 to the second messengers DAG and
IP3, which in turn activate serine/threonine PKC and
facilitate Ca21 mobilization, respectively. The SFK Fyn
associates with PKCd downstream of PLCb, and they
reciprocally activate one another. Increased Ca21
concentration contributes to SFK activation. SFKs lie
upstream of the PI3K/Akt pathway. (Aii) PAR-4 coupled
to G12/13 mediates platelet shape change via the
RhoA/ROCK/MLC pathway. Fyn activated downstream
of G12/13 inhibits signaling via Gq-coupled PAR-4. (B) The
Gi-coupled ADP receptor P2Y12 signals by inhibiting
adenylate cyclase/cAMP/protein kinase A (PKA) and
Gbg-mediated activation of PI3K/Akt. The SFKs Lyn and
Fyn bind directly to the Ga subunit and play a critical role
in initiating signaling via the PI3K/Akt pathway.
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or SFK inhibitor, but it is abolished by a PKC inhibitor in com-
bination with either a Ca21 chelator or SFK inhibitor.6,7,81,82 Further
evidence of the interplay between SFKs and PKC is that PKCd in-
teracts directly with Fyn and is tyrosine phosphorylated at positions
Tyr311 and Tyr565 in an SFK-dependent manner that potentiates
PKC activity in response to thrombin.81 This is consistent with the
earlier ﬁnding that phosphorylation of Ser12 in the membrane-
binding domain of Src by PKC induces cytoskeletal association and
an increase in substrate afﬁnity.83
Fyn has also been implicated as a negative regulator of PAR-4
signaling (Figure 6Aii).12 This is supported by ﬁndings that PAR-
4–induced platelet aggregation and PKC activation are potentiated
in Fyn-deﬁcient platelets but not Lyn-deﬁcient platelets.12 It is
hypothesized that Fyn activated downstream of G12/13-coupled
PAR-4, which signals via the RhoA/ROCK/MLC pathway and
regulates shape change, attenuates Gq-coupled platelet responses
by inhibiting PKC activation and intracellular Ca21 mobilization
(Figure 6Ai-ii).12 The mechanism of activation of Fyn downstream
of G12/13 and how it inhibits Gq signaling remains unknown.
SFKs play a central role in initiating signaling via the Gi-coupled
P2Y12 and a2A receptors. ADP- and adrenaline-induced primary
wave aggregation is inhibited in platelet-rich plasma in the pres-
ence of SFK inhibitors.84 The involvement of SFKs in P2Y12
signaling is supported by ﬁndings that ADP-induced SFK trans-
autophosphorylation is abolished by a P2Y12 antagonist, but not
by a P2Y1 antagonist, and in mouse platelets lacking P2Y12 but
not in Gq-deﬁcient platelets.
7,85 Consistent with these ﬁndings, Gi
signaling is sufﬁcient to activate SFKs, and Lyn and Fyn interact
with Gi in platelets, suggesting that SFKs are direct effectors of Gi
(Figure 6B). SFKs have also been proposed to lie upstream of the
PI3K/Akt pathway activated by the Gbg subunit of Gi (Figure 6B).
7
Akt phosphorylation is inhibited by PP2 in ADP-stimulated
Gq-deﬁcient platelets or platelets treated with a P2Y1 receptor antag-
onist. However, SFKs are not involved in regulating adenylate
cyclase and cAMP levels.7 SFKshave alsobeen implicated in regulating
cross-talk between P2Y1 and P2Y12.
11 According to this model, SFKs
activated downstream of P2Y1 negatively regulate Ca
21 mobiliza-
tion mediated by P2Y12 and PI3K,
11 providing further evidence of
the inhibitory roles of SFKs downstream of GPCRs and mechanistic
insights into how SFKs regulate cross-talk between these receptors.
Hemostatic consequences of inhibiting
platelet SFKs
PTK inhibitors are increasingly used in the treatment of cancer
and inﬂammatory and autoimmune diseases, examples of which
are the Bcr-Abl inhibitors dasatinib, bosutinib, and saracatinib
used as second-line treatments of chronic myelogenous leukemia.86
However, these compounds have off-target effects on other PTKs,
including SFKs. Not surprisingly, they have severe adverse bleeding
effects.86 Recent studies have revealed reduced platelet reactivity
and mild thrombocytopenia in humans and mice treated with
dasatinib, which underlie these adverse effects.87,88 Reduced platelet
counts and normal half-life in dasatinib-treated mice suggest a block
in platelet production. This is supported by delayed platelet recovery
following immune-induced thrombocytopenia and increased num-
bers of megakaryocytes in the bone marrow of these mice.88 Mega-
karyocyte migration toward an SDF-1a gradient and proplatelet
formation were inhibited by dasatinib ex vivo, supporting the hy-
pothesis that dasatinib inhibits platelet production.88 Thus, caution
must be taken when administering PTK inhibitors with known off-
target effects on SFKs, especially when given in combination with
platelet inhibitors, such as aspirin and P2Y12 antagonists. Such
profound hemostatic effects of inhibiting SFKs raise important
questions about the antithrombotic potential of selective and
reversible SFKs inhibitors.
New frontiers and targets
Akey question that remains unresolved is how SFKs are regulated in
platelets. Addressing this questionwill lead to a better understanding
of how the threshold of platelet reactivity is set and the identiﬁcation
of novel antithrombotic drug targets. Only recently have we started
to make some headway into this area of research. Findings from our
group have established CD148 as a global activator of SFKs in
platelets (Figure 7).33 Without it, mouse platelets are less reactive to
collagen, ﬁbrinogen, and to a lesser extent thrombin. Consequently,
CD148-deﬁcient mice exhibit reduced thrombus formation and
a mild bleeding diathesis.33 Consistent with these ﬁndings, poly-
morphisms identiﬁed in the extracellular region of CD148 (Q276R
and R326Q) have a protective effect in the development of heparin-
induced thrombocytopenia through the downregulation of SFK
activity and platelet reactivity,89 raising the possibility of targeting
CD148 in this and thrombotic conditions. Subsequent ﬁndings from
our group revealed that CD148 can also attenuate SFK activity by
dephosphorylating the activation loop tyrosine residue of SFKs
(Figure 7).90 This suggests that CD148 acts as a rheostat that
optimizes SFK activity in resting and activated platelets; however,
the conditions under which CD148 negatively regulates SFKs have
yet to be determined.
The structurally distinct nontransmembrane PTPs PTP-1B
and Shp1 have also been implicated as positive regulators of SFKs
in platelets by a similar mechanism. PTP-1B has been shown to ac-
tivate Src speciﬁcally downstreamofaIIbb3 (Figures 3A and 7),30,91
whereas Shp1 appears to act as a positive regulator of SFKs downstream
Figure 7. Tyrosine phosphorylation–mediated regulation of SFK activity. SFK
activity is regulated through the phosphorylation of conserved tyrosine residues in
the C-terminal tail and activation loop. Phosphorylation of the C-terminal tyrosine
residue inhibits SFK activity by mediating formation of an intramolecular interaction
with the SH2 domain that blocks the active site. A second intramolecular interaction
between the SH3 domain and the proline-rich SH2-kinase linker region maintains the
SFK in an inactive conformation. Dephosphorylation of the C-terminal tyrosine
residue by the protein-tyrosine phosphatases CD148, PTP-1B, and possibly Shp1,
releases the intramolecular interactions and actives the SFK. Maximal activation is
achieved through trans-autophosphorylation of the activation loop tyrosine residue.
Phosphorylation of the C-terminal inhibitory tyrosine residue by Csk or Csk homologous
kinase (Chk) re-establishes the SH2 C-terminal inhibitory phosphotyrosine in-
teraction and returns the SFK to an inactive conformation. Dephosphorylation of the
activation loop tyrosine returns the SFK to a basally active state. CD148 may be
responsible for dephosphorylating this site in platelets.
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of GPVI and aIIbb3 (Figure 7).92 In contrast, SFK activity was
not altered in platelets lacking the structurally related PTP
Shp2,92 demonstrating the speciﬁcity of PTPs. Thus, a picture is
emerging of the central role played by PTPs in regulating SFKs in
platelets.24
Surprisingly little is known about how SFKs are inhibited in
platelets. This also applies to megakaryocytes, which presumably
also contain high levels of SFKs and are continuously exposed
to agonists in the bone marrow that signal via SFKs. There is the
question of why megakaryocytes do not become transformed
under these conditions. Src is, after all, the product of a proto-
oncogene. The prevailing hypothesis is that this is achieved by
Csk, a well-established inhibitor of SFKs in other cell types
(Figure 7).93 Preliminary ﬁndings from Csk conditional knockout
mice have revealed that Csk is indeed a major inhibitor of SFKs in
platelets (J.M. and Y.A.S., unpublished data). Platelets also express
Chk that may work in conjunction with Csk to inhibit subsets of
SFKs under speciﬁc conditions.94 Alternative inhibitory mecha-
nisms cannot be excluded, particularly because platelets contain such
high levels of SFKs.
Other modes of regulation that warrant investigation include
serine phosphorylation, unclamping, and degradation (Figure 8A).
Neither the PKC isoform that phosphorylates Ser12 of Src nor the
Ser/Thr protein phosphatase that dephosphorylates this residue
and regulates the compartmentalization and substrate afﬁnity of
Src have been identiﬁed. Protein-protein interactions can also
activate SFKs by unclamping the intramolecular interactions that
maintain SFKs in inactive conformations (Figure 8B), in which
case dephosphorylation of the C-terminal inhibitory tyrosine
residue is not necessary to active the SFK. Ubiquitin-dependent
degradation is yet another mechanism of downregulation that has
yet to be explored in platelets.
Physiological substrates and interacting partners of SFKs also
remain incompletely deﬁned in platelets. Although seemingly of
little clinical value, answers to these questions could yield novel,
indirect strategies of inhibiting SFKs and their biological effects.
Potential targets could include activators, inhibitors, docking sites,
and downstream effectors of SFKs. The rationale is that more
specialized inhibitors blocking speciﬁc aspects of platelet function
required for thrombus growth and stability will likely have fewer
adverse bleeding effects compared with broad-spectrum SFK
inhibitors.
In conclusion, ﬁndings made over the past 2 decades have ﬁrmly
established SFKs as critical regulators of platelet signaling and
activation. They not only transmit primary activation signals that
initiate and stabilize thrombus formation, they also contribute to
signaling via GPCRs that amplify activation signals and mediate
cross-talk between receptors and negative feedback pathways that
attenuate platelet activation. The distinct and complimentary func-
tions of SFKs are essential for optimizing the platelet response to
all conditions. Despite the vast amount of knowledge that has
accumulated about SFKs in platelets, many important questions
remain unresolved, ﬁrst and foremost the question of how they are
regulated, and second, their involvement in setting the threshold
of platelet reactivity. Answers to these questions could lead to novel,
more specialized SFK inhibitors with antithrombotic potential.
We are optimistic that the next decade will provide important new
insights into the regulation and roles of SFKs in platelets. The
search is far from over.
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Figure 8. Alternative mechanisms of regulation. (A) Established and novel
mechanisms of regulating SFK activity in platelets. (B) Unclamping and activation
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